The results include the notice of the Minister of Health, effective 1st of March 2021.
We track the Minister of Health’s reimbursement decisions and AHTAPol’s statements and recommendations for drugs with no reimbursed equivalents. With our PREDECIZER approach, we analyzed the decision-making practice of the 12-month period from the latest notice compared to the 12-month period of the preceding notice.
The full presentation is available at the following link:
If you have any questions about this analysis, please e-mail us at development@inar.pl
Analysis of the Reimbursement Decision-Making Practice in Poland (March 2021)
